一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-089 号 一心堂药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）近日接到公司股东阮鸿献先生 通知，获悉阮鸿献先生与中信证券股份有限公司（以下简称"中信证券"）达成协议， 将 2022 年 11 月 16 日阮鸿献先生向中信证券申请办理的股票质押融资业务进行到期还 款并解除股票质押，具体事项如下： 一、股东股份质押情况 1、股份质押解除情况 关于公司股东阮鸿献先生部分股票质押融资 到期还款解除质押的公告 | 股东名称 | 是否为控股股 东或第一大股 | 本次解除质 | 占其所 | 占公司 | | | 质权人/ | | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其一致行 | 押股份数量 | 持股份 | 总股本 | 起始日 | 解除日期 | 申请人等 | | | | （万股） | 比例 | 比例 | | | | | | 动人 | | | | | | | ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-088 号 一心堂药业集团股份有限公司 关于公司股东阮鸿献先生进行股票质押登记的公告 | | 是否为控股 | 本次质 | 占其所 | 占公司 | 是否为限 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 股东或第一 | | | | 售股（如 | 为补 | | | 质权 | | | | | 押数量 | 持股份 | 总股本 | | | 质押起始日 | 质押到期日 | | 质押用途 | | 称 | 大股东及其 | （万股） | 比例 | 比例 | 是，注明限 | 充质 | | | 人 | | | | 一致行动人 | | | | 售类型） | 押 | | | | | | 阮鸿献 | 是 | 690 | 3.79% | 1.16% | 否 | 否 | 2023-11-13 | 2024-11-13 | 中信 | 置换股票 | | | | | | | | | | | 证券 | 质押融资 | 1、股份质押基本情 ...

一心为民 全心服务 一心堂药业集团股份有限公司 关于公司股东阮鸿献先生部分股票质押融资 提前还款解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）近日接到公司股东阮鸿献先生 通知，获悉阮鸿献先生与红塔证券股份有限公司（以下简称"红塔证券"）达成协议， 将 2022 年 11 月 28 日阮鸿献先生向红塔证券申请办理的股票质押融资业务部分进行提 前还款并解除股票质押，具体事项如下： 一、股东股份质押情况 1、股份质押解除情况 | 股东名称 | 是否为控股股 东或第一大股 | 本次解除质 押股份数量 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人/ | | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其一致行 | | | | | | 申请人等 | | | | （万股） | 比例 | 比例 | | | | | | 动人 | | | | | | | | 阮鸿献 | 是 | 340 | 1.87% | 0.57% | ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-085 号 一心堂药业集团股份有限公司 关于公司股东阮鸿献先生进行股票质押登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）近日接到公司股东阮鸿献先生 通知，获悉阮鸿献先生与国泰君安证券股份有限公司（以下简称"国泰君安"）达成协 议，2023年11月7日阮鸿献先生将所持公司股票部分质押给国泰君安进行股票质押式回 购交易融资，具体事项如下： 一、股东股份质押情况 | | 是否为控股 | 本次质 | 占其所 | 占公司 | 是否为限 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 股东或第一 | | | | 售股（如 | 为补 | | | 质权 | | | | | 押数量 | 持股份 | 总股本 | | | 质押起始日 | 质押到期日 | | 质押用途 | | 称 | 大股东及其 | （万股） | ...

一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-084 号 一心堂药业集团股份有限公司 关于全资子公司山西鸿翔一心堂药业有限公司收购平遥济仁堂大 药房连锁有限公司 27 家门店资产及其存货的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）第六届董事会第四次临时会议 审议通过《关于全资子公司山西鸿翔一心堂药业有限公司收购平遥济仁堂大药房连锁有 限公司27家门店资产及其存货的议案》，同意公司全资子公司山西鸿翔一心堂药业有限 公司购买平遥济仁堂大药房连锁有限公司27家门店资产及其存货。并发布《关于全资子 公司山西鸿翔一心堂药业有限公司收购平遥济仁堂大药房连锁有限公司27家门店资产 及其存货的公告》（公告编号：2023-065号）。 截至本公告日，已按协议约定完成全部27家门店铺面租赁合同改签，门店固定资产 及存货盘点交接，并取得新的营业执照、药品经营许可证，门店已开始营业。 特此公告。 一心堂药业集团股份有限公司 董事会 2023 年 11 月 8 日 1/1 ...

一心堂药业集团股份有限公司（以下简称"公司"）2023年第15次总裁办公会同意 上海鸿翔一心堂药业有限公司收购上海康君阁大药房连锁有限公司（以下简称"上海康 君阁"）43家门店资产及其存货。并发布《关于全资子公司上海鸿翔一心堂药业有限公 司收购上海康君阁大药房连锁有限公司43家门店资产及其存货的公告》（公告编号： 2023-072号）。 一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-086 号 一心堂药业集团股份有限公司 关于上海鸿翔一心堂药业有限公司收购上海康君阁大药房连锁有 限公司 43 家门店资产及其存货的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 截至本公告日，已按协议约定完成全部43家门店铺面租赁合同改签，门店固定资产 及存货盘点交接，并取得新的营业执照、药品经营许可证，门店已开始营业。 特此公告。 一心堂药业集团股份有限公司 董事会 2023 年 11 月 8 日 1/1 ...

Group 1: Company Performance - The company achieved a revenue of 4.137 billion CNY in Q3, with a cumulative total of 12.813 billion CNY for the year, representing a year-on-year growth of 6.55% [2] - Net profit attributable to shareholders was 181 million CNY in Q3, totaling 686 million CNY for the year, reflecting a growth of 1.26% year-on-year [2] - The net cash flow from operating activities was 1.341 billion CNY, with total assets amounting to 16.322 billion CNY and net assets attributable to shareholders at 7.870 billion CNY [2] Group 2: Store Expansion and Market Coverage - The company operates 10,008 directly-operated stores, with a net increase of 802 stores since the beginning of the year [2] - Stores in Yunnan province number 5,358, accounting for 53.54% of total stores, while non-Yunnan stores total 4,650, representing 46.46% [2] - The company is focusing on expanding its presence in key regions such as Sichuan and Chongqing, which account for 42.65% of total stores with 1,983 locations [3] Group 3: Challenges and Market Conditions - The company faces pressure from policy changes regarding health products, particularly in Kunming, where health products have been restricted from being purchased with medical insurance since January 2023 [3] - A new policy in Kunming aims to alleviate the medication burden for chronic disease patients, impacting sales due to the absence of certain products [3] - The company has 1,231 chronic disease stores and 735 outpatient coordination stores, with pricing policies affecting gross margins [3] Group 4: Strategic Measures for Improvement - The company plans to enhance non-insurance product sales and increase store numbers outside Yunnan to mitigate policy impacts [4] - Focus on improving transaction frequency and customer volume through better disease management services and seamless online-offline integration [4] - Emphasis on efficient supply chain management and inventory turnover to optimize product promotion and reduce operational cycles [4] Group 5: Future Outlook and Business Strategy - The company is actively pursuing franchise opportunities and has integrated the operations of acquired entities to enhance delivery efficiency [7] - Non-pharmaceutical health products are identified as a key growth area, with a focus on personal care and maternal-infant products [11] - The company aims to improve overall profitability through enhanced store group management and supply chain optimization [14]

Group 1: Investor Relations Activity Overview - The investor relations activity was a performance exchange meeting regarding the Q3 2023 report [1] - The event took place on October 31, 2023, from 13:30 to 14:45 at the headquarters of Yixin Tang Pharmaceutical Group [1] - A total of 140 investors participated in the meeting, including representatives from Northeast Securities, Zhongxin Securities, and Oriental Fund [1] Group 2: Participants and Companies - Key participants included Liu Yuteng from Northeast Securities and Shen Mujun from Zhongxin Securities [2] - Other notable attendees were representatives from various investment management companies such as UBS, Pictet, and Temasek [2][3] - The list of participants included 140 individuals from diverse financial institutions, highlighting broad interest in the company's performance [2][3]

Cash Flow and Financial Performance - The company's cash inflow from operating activities reached CNY 12,459,421,828.66, an increase from CNY 11,484,595,842.87 in the previous year, reflecting a growth of approximately 8.5%[21] - The net cash flow from operating activities was CNY 1,340,703,243.26, a decrease of about 9.2% compared to CNY 1,477,301,792.16 in the same period last year[21] - The company reported a significant decrease in cash received from investment activities, with CNY 667,554.40 in the current period compared to CNY 6,947,000.00 in the previous year, marking a decline of 90.39%[7] - The total cash received from other investment-related activities was CNY 37,800,231.75, a substantial increase from CNY 58.47 in the previous year, indicating a growth of 64648834.07%[7] - The company disposed of fixed assets and received a net cash inflow of CNY 23,140,629.20, a remarkable increase of 7184.05% from CNY 317,688.90 in the previous year[7] - Cash inflow from investment activities totaled ¥61,608,415.35, a significant decrease from ¥1,207,552,247.37 in the previous period[22] - Cash outflow for investment activities reached ¥360,650,193.94, compared to ¥1,187,685,921.26 in the prior period, resulting in a net cash flow from investment activities of -¥299,041,778.59[22] - Total cash inflow from financing activities was ¥469,085,282.36, up from ¥250,008,756.05 in the previous period[22] - Cash outflow for financing activities increased to ¥1,557,557,768.38 from ¥1,112,346,321.34, leading to a net cash flow from financing activities of -¥1,088,472,486.02[22] - The net increase in cash and cash equivalents was -¥46,387,004.57, contrasting with an increase of ¥635,284,039.19 in the previous period[22] - The cash flow from operating activities showed a significant increase, indicating better liquidity management and operational efficiency[45] - The cash and cash equivalents decreased by 107.30% to approximately -¥46.39 million, influenced by asset disposals and significant investments[52] Revenue and Profitability - The total operating revenue for the current period reached ¥12,812,828,974.03, an increase of 6.55% compared to ¥12,025,419,077.72 in the previous period[45] - The operating profit for the current period was ¥786,496,404.26, up from ¥746,374,123.24 in the previous period, reflecting a growth of 5.4%[37] - The net profit attributable to shareholders of the parent company was ¥685,920,712.36, compared to ¥677,365,857.29 in the previous period, indicating an increase of 1.6%[38] - The total comprehensive income for the current period was ¥691,886,329.28, compared to ¥672,837,257.58 in the previous period, showing an increase of 2.5%[38] - Revenue for the reporting period reached ¥4,137,293,221.03, an increase of 1.89% year-over-year[80] - Net profit attributable to shareholders was ¥181,345,036.19, a decrease of 30.02% compared to the same period last year[80] - Net profit excluding non-recurring gains and losses was ¥174,048,756.36, down 30.33% year-over-year[80] - Basic earnings per share were ¥0.3050, reflecting a decline of 30.11% from the previous year[80] - Diluted earnings per share stood at ¥0.3053, a decrease of 29.93% compared to the same period last year[80] Assets and Liabilities - The total assets increased from CNY 16.18 billion at the beginning of 2023 to CNY 16.32 billion by September 30, 2023[74] - The total liabilities increased by 68.32% due to the expansion of traditional Chinese medicine business, indicating strategic growth initiatives[50] - The total liabilities decreased from CNY 8.65 billion at the beginning of 2023 to CNY 8.33 billion by September 30, 2023[74] - The company's equity attributable to shareholders increased from CNY 7.43 billion at the beginning of 2023 to CNY 7.87 billion by September 30, 2023[74] - Total assets at the end of the reporting period amounted to ¥16,321,717,499.21, an increase of 0.88% from the end of the previous year[80] - Shareholders' equity attributable to the parent company was ¥7,869,699,466.54, up 5.97% year-over-year[80] Investments and Research - The company plans to enhance customer engagement through CRM systems and personalized services, aiming to improve customer satisfaction and loyalty[44] - Research and development expenses increased to ¥7,649,444.02, up from ¥3,851,636.92, marking a rise of 98.5% as the company focuses on innovation[45] - Research and development expenses rose by 98.60% to approximately ¥7.65 million, reflecting the formation of new R&D projects[60] - The company established a research and development center in Chengdu to support digital transformation and market expansion[70] Operational Expansion - The company has established 13 logistics distribution centers, with the Yunnan warehouse being the largest, supporting over 5,000 stores in Yunnan and providing distribution capabilities to subsidiaries outside the province[13] - The company signed a share transfer agreement to acquire 100% equity of Shanghai Xuyuan Fire Technology Service Co., enhancing its logistics capabilities in the Shanghai region for pharmaceutical retail chain operations[13] - The total number of direct-operated stores increased by 802 to 10,008, with a notable expansion in non-Yunnan regions, particularly in the Sichuan-Chongqing area, which now accounts for 42.65% of the total store count[66] - The company plans to adjust its product categories to include health-related products, cosmetics, and personal care items to enhance market competitiveness[67] - The self-operated business will focus on filling service gaps and expanding the non-pharmaceutical supply chain[71] - The company plans to enhance the integration of O2O business with offline operations to improve operational efficiency[71] Miscellaneous - The effective membership count reached 41.8 million, contributing to a higher repurchase rate and solidifying the customer base for future growth[44] - Government subsidies recognized in the current period totaled ¥2,276,718.19, down from ¥12,561,517.27 previously[25] - Non-current asset disposal gains amounted to ¥8,239,907.53, compared to a loss of -¥2,930,486.73 in the previous period[25] - Cash received from minority shareholders increased significantly by 205,700.56% to approximately ¥18.02 million, indicating increased investment[52] - The total sales of the new retail business reached CNY 599 million from January to September 2023, with O2O business contributing CNY 483 million[71] - Accounts receivable decreased from CNY 1.73 billion at the beginning of 2023 to CNY 1.68 billion by September 30, 2023[72] - Inventory increased from CNY 3.39 billion at the beginning of 2023 to CNY 3.83 billion by September 30, 2023[73] - Prepayments rose by 44.09% to ¥12,790,882.76, driven by advances for leasing and franchise fees[28] - The construction in progress increased by 152.59% to ¥9,764,165.35, attributed to new projects initiated during the reporting period[28]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-081 号 一心堂药业集团股份有限公司 第六届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 一心堂药业集团股份有限公司（以下简称"公司"）第六届监事会第四次会议于 2023 年 10 月 30 日 9 时整在公司会议室召开，本次会议于 2023 年 10 月 19 日通过邮件和书 面形式发出通知。本次会议应出席会议的监事为 3 人，实际出席会议的监事为 3 人。本 次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 会议由冯萍女士主持。与会监事逐项审议了有关议案并做出决议如下。 二、监事会会议审议情况 1．审议通过《关于公司 2023 年第三季度报告的议案》 《2023年第三季度报告》具体内容详见公司指定信息披露媒体巨潮资讯网 （www.cninfo.com.cn）。并批准2023年第三季度财务报告对外报出。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 备查文件： 1、《一心堂药业集团股份有 ...